Introduction
Coronary artery disease (CAD) remains one of the major causes ofmortality in the developed countries of the world. In the last year or two there have been a series of papers reporting the effects of a number of drugs on various management problems. These have shown, for example, that thrombolytic therapy has a major impact on early mortality and have also investigated the most effective way of producing clot lysis.' In addition, the role of angiotension converting enzyme (ACE) inhibitors has been extended to include the management of the post-infarct patients. The Survival and Ventricular Enlargement (SAVE) study2 suggested a major role for captopril in the long-term management of patients following myocardial infarction who had impaired myocardial function and the more recent Acute Infarction Remipril Efficacy (AIRE) study3 has shown that ramipril reduces mortality in the first 30 days.
Further progress is more likely to be made if a more co-ordinated approach to the management of the at risk patient is developed. The accepting of certain principles is likely to help. Firstly, the importance of prophylaxis in coronary artery disease has to be more widely recognized. At least one half of all myocardial infarcts are silent. 4 They are recognized because repeated electrocardiograms (ECGs) demonstrate changes over a period of time. These silent infarcts carry a prognosis as bad as having had a recognized clinical infarct. 5 Since these episodes are by definition not recognized they cannot be treated and the damage which they cause cannot be reduced. If possible, therefore, they must be prevented. Coronary artery disease may also present as sudden death. It is believed that between 1/6th and 1/3rd of all Correspondence: M.J. Kendall, M.D., F.R.C.P. Received: 9 December 1993 myocardial infarcts present with sudden death as the first, last and only manifestation ofthe disease. 6 Patients who smoke and who have hypertension and particularly those who have left ventricular hypertrophy are at particular risk. Only if medical help is immediately available in a suitable environment can the patient be helped. Once again, therefore, the only effective option is prevention.
Secondly, although it is accepted that there are many risk factors for coronary artery disease, in clinical practice the doctor tends to concentrate on one risk factor. Thus patients attending the hypertension clinic often do not have their plasma lipids measured, and the doctor treating a woman with hyperlipidaemia tends not to consider hormone replacement therapy. Patients who are developing ischaemic heart disease may be at risk from hypertension, hyperlipidaemia, thromboembolism, arrhythmias and, in women, the postmenopausal state. Simple logic suggests that a five-sided attack requires a five-sided pharmacological response: that is, the doctor has to consider the need to create a 'pentagon of protection'. In addition, non-pharmacological measures may be as important as drug treatment and efforts directed towards Five major coronary risk factors amenable to pharmacological intervention (the 'Pentagon of Protection') include hypertension, hyperlipidaemia, thromboembolism, arrhythmias and the postmenopausal state.
A cardioprotective drug reduces the risk of suffering or dying from a coronary event. Ideally, this should have been proven in properly performed clinical trials of primary or secondary prevention.
One half of all myocardial infarctions are silent and a significant proportion of the rest may present as sudden death.
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Thirdly, where possible, doctors treating the five disorders described above should use drugs which have cardioprotective potential wherever possible. This implies that cardioprotection is clearly defined, that doctors recognize that preventing the patient dying from a coronary event is a priority for certain 'at risk groups', that the impact ofthe drugs on coronary artery disease is known and the prescribing doctor is aware of what has been established in this context. Current prescribing practices suggest that this is not the case and this review is written with the intention of addressing this problem. Thus we shall describe briefly the impact of drugs used to treat hypertension, hyperlipidaemia, thromboembolic disease, arrhythmias and the postmenopausal state on the risk of dying from a coronary event. In addition, other pharmacological measures which may be taken to reduce endothelial damage will be described.
At this point the concept of a cardioprotective drug requires consideration. This term will be downgraded and it is often considered a marketing term. In this review cardioprotective is used to describe drugs which reduce the risk of suffering or dying from a coronary event. In most instances this would imply that the drug can be shown to prevent or delay the development of a coronary occlusion and/or reduce the risk of developing ventricular fibrillation. More importantly, a cardioprotective drug should have been shown in properly performed clinical trials to prevent the first coronary event (primary prevention) or prevent death or a recurrence in those who survive their first heart attack (secondary prevention). Since the pathological processes are the same in primary and secondary prevention, a drug which is effective in one should be effective in the other. However, since most of those who have had an infarct have established and often extensive coronary artery disease, they are at much greater risk and therefore it is much easier to demonstrate the efficacy of a drug in secondary prevention trials. By comparison patients selected for inclusion in primary prevention trials may be at low risk and it is virtually impossible to show an effect by correcting one mildly abnormal risk factor. Thus modest reductions in the blood pressures of mildly hypertensive middle aged females will have little impact.
Hypertension (1) Thiazide diuretics
Thiazides tend to produce metabolic effects which would increase the coronary risk and they have not been shown to have cardioprotective actions in animal models. In many primary prevention trials such as the Australian Mild Hypertension Trial,7 diuretics did not reduce the coronary mortality and morbidity. In the review of the treatment of hypertension by McMahon and colleagues' in which the impact on coronary artery disease was modest, most ofthe trials quoted were assessing the effects of thiazides. However, the recent Medical Research Council elderly hypertension study9 and the SHEP study'0 did show a reduction in coronary events in those on thiazides. This observation has not been explained. In the Systolic Hypertension in the Elderly Programme (SHEP) study there was no reduction in sudden death and no data on this were provided in the MRC study. It is possible that thiazides have some impact on coronary events in the elderly but overall thiazides could not be considered cardioprotective.
(2) Beta adrenoceptor blocking drugs (beta blockers)
There is an extensive literature on the effects ofbeta blockers on the processes which led to death from ischaemic heart disease. Thus beta blockers reduce endothelial damage,"I atheroma formation'12"3 and tend to inhibit clot formation. '4 In addition three studies have demonstrated that in three different animal models, in three different centres, beta blockers have been shown to reduce the risk of developing ventricular fibrillation.'5"'7 Of some interest is the fact that in one'5 propranolol was given into the cerebral ventricles and in the third'7 a relationship with vagal tone was demonstrated both suggesting that lipophilic beta blockers which enter the brain more readily might be expected to be more effective.
The biochemical effects of beta blockers, however, are a cause for concern. Though they probably produce adverse effects which are less severe and occur less often than after diuretics, there is no doubt that beta blockers, particularly non-selective beta blockers, tend to reduce high density lipoprotein (HDL) cholesterol, increase triglycerides and they have unwanted effects on glucose handling.
Primary prevention studies with beta blockers have been the cause ofdisappointment and dispute. however, beta blockers appeared to reduce coronary mortality in two non-randomized studies '8"9 and High plasma renin activity is an independent marker for increased risk of myocardial infarction48 and ACE inhibitors would be expected to reduce the effects of this. Insulin resistance and hyperinsulinaemia have also, more recently, been associated with susceptibility to develop ischaemic heart disease and ACE inhibitors tend to correct this whilst diuretics tend to make the situation worse. 49 Clinical trial data are derived from heart failure and secondary prevention studies rather than from primary prevention trials. In VHEFT 247 enalapril and in the HY-C trial' captopril reduced the incidence of sudden death in heart failure patients. Myocardial infarcts were less frequent in the enalapril arm of the SOLVD trial (Studies of Left Ventricular Dysfunction)5" than in the placebo arm. Many of these patients with heart failure would have had extensive coronary artery disease and the means by which the ACE inhibitors seemed to reduce coronary event risk is not adequately explained.
The two secondary prevention studies also show that ACE inhibitors have a cardioprotective effect but pose further questions. In the SAVE study2 captopril had little effect for over a year but thereafter, in a large number of post-infarct patients with left ventricular dysfunction, it markedly influenced outcome in various ways including reducing reinfarction rates. In the more recently published AIRE Study'3 ramipril given between day 3 and day 10 after an acute infarct reduced overall mortality and was seen to have a beneficial effect after 30 days treatment.
In conclusion, ACE inhibitors have not hitherto been considered to be cardioprotective drugs. However, the results of recent studies indicate that ACE inhibitors do have a cardioprotective role so far demonstrated only in secondary prevention studies.
Hyperlipidaemia
The role of hyperlipidaemia and the problems associated with lipid reduction have been the subject of a number of reviews and publications recently.52-It is not necessary to review this important subject again in great detail, we will briefly summarize the situation as we see it and give a few relevant references.
Since hyperlipidaemia has been a subject of some controversy, it is easy to come to the conclusion that nothing about this subject is certain. It may be helpful to state categorically at this stage that there is little doubt that hyperlipidaemia is an important risk factor for coronary artery disease but that the controversy surrounds the benefits to be derived from lowering plasma lipids and perhaps the ways in which this aim is achieved.
Hyperlipidaemia is an important risk factor. One of the major constituents of the atheromatous plaque is lipid. Countries whose populations have a Although hyperlipidaemia is strongly associated with coronary risk, trials of lipid-lowering drugs have failed to have an impact on total mortality despite a reduction in coronary deaths.
high intake of saturated fats have an increased risk of developing coronary artery disease, subpopulations within countries who have high lipid levels are at greater risk of developing coronary artery disease, and families who have particularly high serum cholesterol levels and who suffer from familial hypercholesterolaemia are at particularly high risk of developing premature ischaemic heart disease.55'56 Furthermore, in general terms, if the cholesterol is lowered the risk of developing coronary artery disease is reduced.57'58 In relation to lipid lowering there have been at least three areas of controversy. Firstly though dietary factors are believed to play a part in causing hyperlipidaemia and dietary modification is the first line treatment for hyperlipidaemia, formal trials of dietary modification may not show a significant improvement in plasma lipids,59 although many are convinced about the value of dietary intervention. This overall lack of effect is because some patients respond and some do not. Since some who do respond are spared the need to take lipid-lowering drugs, dietary advice is considered 'worth a try' in the first instance in most hyperlipidaemic patients.
The second problem is that lipid-lowering therapy has reduced coronary events rather than total mortality,57'58 although in one prolonged study a nicotinic acid derivative did reduce total mortality.' The third concern is that lipid-lowering therapy has been associated with an increase in non-coronary mortality, although the numbers affected have been small and a logical explanation has not been found. These problems have recently been addressed and the guidelines of the British Hyperlipidaemia Association published in the Postgraduate Medical Journal.61
In conclusion, hyperlipidaemia is a coronary risk factor and lipid-lowering drug therapy has been shown to reduce coronary risk. It is not possible to comment on the cardioprotective potential of individual drugs or drug groups. Attempts have not been made in this review to comment further on indications for starting treatment or the choice of therapy.
Thromboembolism
Thrombus formation and plaque rupture are believed to be the final step in the development of a coronary occlusion. It follows that pharmacological interventions directed towards preventing thrombus formation or increasing the rate of thrombus dissolution should reduce the risk of myocardial infarction. Aspirin to reduce platelet aggregation, anticoagulants to prevent clotting and fibrinolytics to encourage thrombus breakdown have all been evaluated in clinical studies. Recent studies all tend to suggest that warfarin therapy will reduce coronary mortality in postinfarct patients and that further studies specifically designed to assess the role of warfarin in postinfarct patients are needed. An earlier study in patients over 60 years73 showed that when patients on warfarin were randomized to continue or to stop, those who continued had a 26% lower mortality and 55% lower reinfarction rate. In the AIMS trial74 infarct patients treated with thrombolysis followed by warfarin had the greatest reduction of in-hospital mortality seen in any trial of thrombolytic therapy. This observation was confirmed in another retrospective analysis of the effects of thrombolysis and oral anticoagulation.7 Finally, in the Warfarin Reinfarction trials,76 oral anticoagulants or placebo were given to 1,214 patients about 3-4 weeks post-infarction and, over the period of follow-up, the mortality rate and reinfarction rate were 24% and 34% lower, respectively, in the actively treated group. By today's standards the clinical trial data on warfarin are not good, but the data available strongly suggest that warfarin effectively reduces mortality and morbidity in post-infarction patients. We do not know whether it is more effective than aspirin, nor do we know whether warfarin plus aspirin would be more effective than either given alone.
Low-dose aspirin is to be recommended for any patient with clinical evidence of atherosclerotic vascular disease. The early studies in which beta blockers were given to post-infarct patients showed that the risk of sudden death could be reduced by timolol,28 metoprolol30 and propranolol. 29 Furthermore it has been demonstrated that the life-saving effect was achieved by reducing the incidence of ventricular fibrillation.7980 Since other drugs are much more effective then beta blockers in the short-term control of ventricular arrhythmias, it seemed very logical to assess the effects of newer agents like flecainide and encainide on the long-term suppression of ventricular arrhythmias. However, the CAST study8' showed that this anti-arrhythmic drug therapy was associated with an increased incidence of arrthymias and mortality. A metaanalysis of ten randomized trials of all class I anti-arrhythmic drugs82 strengthens the findings of the CAST study. Clearly, further evaluation of this problem is needed but, for the moment, this group of drugs cannot be considered as suitable for long-term preventative therapy in the type of patients included in these trials. Further, efforts directed towards providing optimal anti-arrhythmic therapy based on detailed electrophysiological studies failed to show that individualized drug therapies were better than metoprolol. 83 The role of amiodarone requires further consideration. This drug causes potentially serious adverse effects in a large proportion of the patients treated. 84 However, it does appear effectively to reduce the frequency of serious ventricular arrhythmias.85
In conclusion there has been a reasonable expectation that antiarrhythmic drugs would reduce mortality and particularly sudden death in patients at risk which would include all post infarct patients. At the moment beta blockers appear to be the simplest and most effect way of achieving this aim.
The postmenopausal state
Coronary artery disease is often wrongly considered a disease which predominantly effects men. However, although in middle age most patients with clinical evidence of coronary disease are male, the female to male ratio increases rapidly in those over 55 years old.86 Eventually the overall impact of ischaemic heart disease on the two sexes is comparable. In spite of this, female patients have not been investigated and treated with the same diligence as men. 87 Hormone replacement therapy (HRT) helps the postmenopausal woman in many ways, but the potential impact on coronary disease is particularly impressive. Unfortunately the relationship between HRT and CAD is not as clearly defined as it should be. The problems are: (a) the effects of oestrogens and progestogens are different; (b) proper randomized prospective double-blind trials have not been performed; and (c) the clinical effect tends to be a reduction in coronary deaths rather than total mortality.
(1) Mechanisms HRT has marked effects on lipids88 but also beneficially influences blood flow, prostacyclin, other relaxing factors and platelet function.89 90 The improvement in plasma lipids produced by oestrogen therapy is well documented; there tends to be a return to premenopausal concentrations brought about by a reduction in LDL-cholesterol and an increase in HDL-cholesterol.9"92 Progestogens cannot be considered as a single entity as different
The incidence of coronary disease increases rapidly in women during the postmenopausal years.
Hormone replacement therapy has a major protective role against coronary disease in the postmenopausal female. Important diseases where free radical damage is believed to have a role in the pathogenesis include atherosclerosis, ischaemia-reperfusion injury and hypertension. In all cases, the potential for antioxidant therapeutic interventions is currently under investigation as a simple means of limiting free radical damage preventing disease progression.
(1) Atherosclerosis: the oxidative-modification hypothesis Basic research has now advanced our understanding of some of the biochemical events that lead to the development of the atherosclerotic plaque.'09 Most of the cholesterol in the mature lesion originates from circulating low-density lipoprotein (LDL) particles which have been ingested by subendothelial macrophages. However, macrophages in culture when exposed to high concentrations of native LDL do not accumulate cholesterol partly due to downregulation of LDL receptor numbers in the cholesterol-replete state. In contrast, oxidatively modified forms of LDL are much more avidly taken up by cultured macrophages which are converted to cholesterol-laden 'foam cells' characteristic of the atherosclerotic lesion. The rapid uptake of the oxidatively modified LDL has been attributed to a new receptor known as the 'scavenger receptor' which is not downregulated by cholesterol accumulation'09"0 ( Figure 1 ). Although oxidation of LDL is not likely in the circulation, all of the cells of the vessel wall -endothelial cells, smooth muscle cells and macrophages -can modify LDL in vitro and the presence of oxidized LDL in vivo has been established."' "2 Not only is oxidized LDL atherogenic by virtue of its rapid uptake by macrophages but it is also a chemoattractant for macrophages, cytotoxic to endothelial cells, stimulates auto-antibody formation and interferes with endothelium-dependent vasodilatation.'09
With these discoveries, the oxidative-modification hypothesis of atherosclerosis was established and further research directed towards the factors that influence the susceptibility of the human LDL particle to oxidation. One of the most important appeared to be its content of natural antioxidant vitamins, particularly vitamin E and beta-carotene. "' These vitamins protect the core polyunsaturated fatty acids whose oxidation provides most of the toxic products that produce the altered biological properties of oxidized LDL. In vitro measurements of the appearance of these products in LDL subjected to oxidative stress suggest that not until all of the vitamin E is oxidized can lipid peroxidation begin. Accordingly, LDL supplemented with vitamin E is much harder to oxidize in vitro. The function of vitamin E in protecting LDL from oxidation may also depend on its close biochemical relationship with the water-soluble antioxidant vitamin C. The latter can regenerate oxidized vitamin E back to its antioxidant form thus maintaining the antioxidant pool within each particle."' The exact antioxidant function of betacarotene is unclear but it seems to act synergistically with vitamin E being particularly active at low partial pressures of oxygen.
Initial trials of antioxidant vitamins and drugs such as probucol and beta-hydroxytoluene in animal models of atherosclerosis yielded promising results suggesting that the atherogenic process could indeed be retarded."5 This information suggested that antioxidant therapy might yield positive benefits in the human disease. Evidence for the potential influence of antioxidants on atherosclerosis in man has already accumulated from epidemiological surveys linking low levels of antioxidant vitamins with ischaemic heart disease. The WHO/MONICA project compared the risk of ischaemic heart disease mortality with mean plasma antioxidant levels in 12 European populations with normal cholesterol levels (5.7-6.2 mmol/ 1).116 Both absolute and lipid-standardized vitamin E concentrations showed a strong inverse correlation with mortality (r2 = 0.63, P = 0.002 and r2 = 0.73, P = 0.0004, respectively). A similar inverse correlation was found for vitamin C (r2 = 0.41, P = 0.03) but not for beta-carotene (r2 = 0.21, P = 0.14). In a case control study of 6,000 men aged 35-54 years in Edinburgh, antioxidant vitamin levels were measured in 1 10 angina patients identified by the WHO Chest Pain questionnaire and compared with 394 controls randomly selected from the sample."7 The unadjusted risk of angina was significantly higher in the lowest quintile compared with the highest for vitamin E (odds ratio 2.51, 95% CI 1.24-5.10), vitamin C (odds ratio 2.35, 95% CI 1.16-4.78) and beta-carotene (odds ratio 2.64, CI 1.32-5.29). The relationship with vitamin E remained significant after controlling for smoking, cholesterol, blood pressure, weight and age. Studies of dietary habits have also associated a high calculated dietary intake of vitamin E, vitamin C and beta-carotene with ii Figure 1 The oxidative-modification theory of atherosclerosis.
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originally recruited in 1982.124 A history of angina pectoris or revascularization prior to randomization was reported in 333 cases. Of these 160 were assigned to beta-carotene and 173 to placebo. After a mean follow-up of 60.2 months, a significant reduction in cardiovascular events was seen in the actively treated group (relative risk = 0.46, 95% CI = 0.24-0.85). The trial is continuing and further information about the primary prevention of cardiovascular events should be available in the mid-1990s. In Britain the combined Medical Research Council and British Heart Foundation Heart Protection Study is about to begin and will test the effects of a combined antioxidant preparation as well as an HMG CoA reductase inhibitor in a 2 x 2 factorial design in preventing coronary disease in high-risk groups. The effects ofa mixture of antioxidants will also be tested in 15,000 men and women in the SUVIMAX trial in France. These trials will not only help to define the role of antioxidants in preventing atherosclerosis but will also offer information about the safety of longterm vitamin supplementation, so far assumed to be free of risk.
(2) Ischaemic-reperfusion injury Reperfusion of ischaemic myocardium is a common phenomenon in cardiological practice. For patients with established ischaemic heart disease episodes ofangina that terminate spontaneously or in response to pharmacological intervention are regular events. Many episodes may even occur unnoticed (silent myocardial ischaemia). Reperfusion is an increasingly available therapeutic option with the advent ofpost-infarction thrombolysis, surgical revascularization, coronary angioplasty and cardiac transplantation. The readmission of blood and oxygen to previously ischaemic tissues often results in the release of large amounts of oxygen-derived free radicals.125 This probably occurs because during the ischaemic period the handling of oxygen by the mitochondrial electron transport system and enzymes such as xanthine oxidase is disrupted yielding incomplete reduction products, most notably the superoxide radical. While the reactivity of superoxide alone is not high it has the potential to interact with transition metal ions (also made available in ischaemic damaged tissues) to produce the highly damaging hydroxyl radical. The harmful effects of free radical activity may be exerted on the sarcoplasmic reticulum and other membranes where loss ofthe ability to handle calcium and other ions is a hallmark of reperfusion.126 When the myocardium is reperfused potentially harmful sequelae include post-ischaemic contractile dysfunction ('stunning'), reperfusioninduced arrhythmias and endothelial damage. [127] [128] [129] These pathophysiological changes are paralleled by biochemical evidence of free radical activity and consequent oxidative damage. Increased levels of lipid peroxides have been detected after successful thrombolysis following acute myocardial infarction'30 and following percutaneous coronary angioplasty.'3' Coronary angioplasty has also been associated with increases in the markers of endothelial damage. '29 A number of therapeutic options exist for reducing the impact of reperfusion on the myocardium with almost all of the evidence deriving from animal studies. Agents such as superoxide dismutase, catalase, vitamin E, allopurinol and its metabolite oxypurinol (inhibitors of xanthine oxidase), sulphydryl compounds such as glutathione and captopril, and iron-chelating agents such as desferrioxamine have been used to improve outcome in various animal models.'32",33 However, the design and end-points of the studies have been variable and it is not clear if the results can be easily extrapolated to the clinical setting. The human myocardium differs in some respects in possessing little xanthine oxidase and having a collateral circulating unlike some other species. Defects in calcium homeostasis are also a feature of reperfusion injury, possibly as a direct result of free radical activity,'26 and calcium-channel blocking drugs such as verapamil and diltiazem have been shown to reduce stunning, infarct size and endothelial disruption in animal models.'33"134
The possible role of oxidative mechanisms in the pathophysiology of hypertension is less clear. Hypertension has been associated with low levels of antioxidant vitamins, particularly ascorbic acid,'35 and infusions of antioxidants into hypertensive subjects can reduce blood pressure.'36 This approach is supported by studies that have linked hypertension to antagonism of nitric oxide vasodilatation by the superoxide radical.'37 Some commonly prescribed anti-hypertensive agents including the angiotensin-converting enzyme inhibitor captopril are acknowledged as free radical scavenging agents in vitro. However, the low circulating concentrations (nanomolar) found in vivo are strongly against a bulk scavenging role for these agents when compared with the natural scavenging antioxidants (micromolar). Since the goal of antihypertensive therapy is to avoid the major complications of which atherosclerosis is the most common, we might still be persuaded to adopt antioxidants for their preventative role even in the absence of benefits in blood pressure reduction. Conclusion The possibility that antioxidant therapy may have an impact on human disease looks particularly group.bmj.com on November 7, 2017 -Published by http://pmj.bmj.com/ Downloaded from Chelates iron and prevents it acting as a template for formation of the highly damaging hydroxyl radical Inhibits production of the superoxide radical by the enzyme xanthine oxidase. Used with some success in some animal models of reperfusion injury promising in atherosclerosis. In this preventative role, treatment will necessarily last for many years and for this reason supplementation of the diet with natural antioxidants seems to be the safest approach. The results of prospective studies are keenly awaited. Many episodes of myocardial reperfusion following ischaemia are predictable (thrombolysis, coronary angioplasty, cardiac surgery) and therefore potentially amenable to intervention with antioxidant therapies. As yet convincing evidence for any benefit of antioxidant intervention is not available. The finding that streptokinase thrombolysis is associated with excess mortality in the first 24 hours compared to placebo" will continue to stimulate interest in the biochemical events associated with reperfusion and in adjunctive therapy that might make this period safer.
Although several drugs used in cardiovascular therapeutics are claimed to have antioxidant properties, it is unlikely that any play an important role in scavenging free radicals in vivo because of their low concentrations. This does not rule out the possibility that they reduce free radical activity secondary to modification ofthe underlying disease process. Work is continuing to discover agents that can supplement the natural antioxidant systems (Table II) . However, synthetic compounds are unlikely to possess the versatility of their natural counterparts. For instance, vitamin C is not only a scavenging antioxidant in its own right but can regenerate other antioxidants such as vitamin E, and can itself be regenerated by intracellular reduction.'06At present, the most attractive approach to antioxidant therapy appears to be manipulation of endogenous antioxidant systems and natural vitamins. 
